Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from ongoing phase 2, randomized, open-label ENSURE study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
May 7-10, 2025
Amsterdam the Netherlands


Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from ongoing phase 2, randomized, open-label ENSURE study

	EASL 2025 May 7-10 Amsterdam